Titan Pharmaceuticals INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
Titan Pharmaceuticals, Inc. files a supplement to its proxy statement, updating details on its business combination with Black Titan Corporation, including an increase in the Series A Preferred Shares PIPE financing to $6 million.
Titan Pharmaceuticals, Inc. filed a supplement to its proxy statement, incorporating Black Titan Corporation's updates regarding a proposed business combination, including increased share capital and a new placement agent for future financing.
Titan Pharmaceuticals, Inc. has filed a definitive proxy statement (DEFA14A) with the U.S. Securities and Exchange Commission.
DEFM14A: Titan Pharmaceuticals to Merge with Black Titan and TalenTec in Strategic Reverse Recapitalization
Titan Pharmaceuticals, Inc. (TTNP) is set to undergo a reverse merger with Black Titan Corporation (PubCo) and acquire Malaysia-based human capital management solutions provider TalenTec Sdn. Bhd., aiming to revitalize its business and list the combined entity on Nasdaq under the symbol BTTC.
DEFA14A: Titan Pharmaceuticals Seeks Stockholder Approval for Key Proposals at Upcoming Annual Meeting
Titan Pharmaceuticals is soliciting proxies for its Annual Meeting of Stockholders to be held on June 16, 2025, covering director elections, plan amendments, stock issuance, auditor ratification, executive compensation approval, and say-on-pay frequency.
Titan Pharmaceuticals is holding its annual meeting on June 16, 2025, seeking stockholder approval for several key proposals, including a share issuance related to a private placement, an amendment to its equity incentive plan, and the ratification of its independent auditor.